Investigating the link between laryngopharyngeal reflux and idiopathic pulmonary fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the Supraglottic Index (SGI) as a reliable measure for identifying the presence and severity of laryngopharyngeal reflux (LPF) in patients with idiopathic pulmonary fibrosis (IPF). The researchers hypothesize that the SGI will show a stronger correlation with IPF severity compared to traditional gastroesophageal reflux (GER) data obtained from pH/impedance probes. Participants will be monitored over time to assess the relationship between SGI and IPF progression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of IPF
* Age 40-95
* Able to read, speak, and understand English
* If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.

Exclusion Criteria:

* Patients who do not meet all inclusion criteria
* Pregnant females

Where it's running

• National Jewish Health
  Denver, Colorado, United States Recruiting

Study contacts

• Principal investigator: Matthew Koslow, DO — National Jewish Health
• Study coordinator: Matthew Koslow, MPH
• Email: ILDresearch@njhealth.org
• Phone: 303-398-1996

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Single-dose safety and pharmacokinetics of HW241045 in healthy adults

  This trial will test single ascending doses of HW241045 in healthy adults (18–55) to see if the drug is safe, well tolerated, and how it is processed by the body.

  Recruiting Phase 1 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Beijing · NCT07448194

• Mechanism-guided treatment versus proton-pump inhibitor therapy for chronic throat symptoms

  This trial will test whether a mechanism-guided approach combining personalized acid-suppression and voice therapy helps adults (18–89) with chronic throat symptoms more than usual proton pump inhibitor (PPI) treatment.

  Recruiting Phase 4 University of California, San Diego · San Deigo, California · NCT06999577

• Evaluating SB17170 in patients with idiopathic pulmonary fibrosis

  This study is testing a new drug called SB17170 to see if it can help adults with moderate to severe idiopathic pulmonary fibrosis breathe better over 12 weeks.

  Recruiting at 2 sites Phase 2 SPARK Biopharma · Goyang and 4 other locations · NCT06747923

• Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients

  This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06644144

• Exploring the links between sleep hygiene, muscle loss, and brain function in lung disease

  This study looks at how good or bad sleep affects muscle loss and brain function in people with lung diseases like COPD and IPF.

  Recruiting National Hospital Organization Minami Kyoto Hospital · Jōyō, Kyoto · NCT05193136

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.